Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

November 30, 2013

Conditions
Untreated Mantle Cell Lymphoma
Interventions
DRUG

Bevacizumab

15 mg/kg on day 1 of each of 6 cycles

DRUG

Rituximab

"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"

DRUG

CHOP

Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7

Trial Locations (2)

10021

Weill Medical College of Cornell University, New York

60612

Rush University Medical Center, Chicago

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT00401817 - Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter